An Unusual Case The Revival of Thalidomide

EMEA European Agency for the Evaluation of Medicinal Products 

1 DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003) The price of innovation new estimates of drug development costs. Journal of Health Economics, 22, 151-185. 

2 Lasser, K.E., Allen, P.D., Woolhandler, S. ]., Himmelstein, D.U., Wolfe, S.M. and Bor, D.H. (2002) Timing of new black box warnings and withdrawals for prescription medications. The Journal of the American Medical Association, 287, 2215-2220. 

3 Graham, G.K. (2002) Postmarketing surveillance and black box warnings (To the Editor). The Journal of the American Medical Association, 288, 955-956. 

4 Prentis, R.A., Lis, Y. and Walker, S.R. (1988) Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964—1985). British Journal of Clinical Pharmacology, 25, 387—396. 

---